nitrogenase stabilizing-protective protein, bacteria has been researched along with mdv 3100 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beretta, GL; Carloni, S; Castoria, G; De Cesare, M; Del Rio, A; Di Donato, M; Ferroni, C; Guerrini, A; Leonetti, C; Paganelli, G; Porru, M; Tesei, A; Varchi, G; Zaffaroni, N; Zamagni, A | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Kandil, S; McGuigan, C; Pertusati, F; Westwell, AD | 2 |
| Beretta, GL; Cortesi, M; De Cesare, M; Ferroni, C; Guerrini, A; Kim, YS; Lee, S; Malhotra, SV; Parenti, MD; Pepe, A; Tesei, A; Trepel, JB; Varchi, G; Zaffaroni, N; Zamagni, A | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Giancotti, G; McGuigan, C; Pertusati, F; Westwell, AD | 1 |
| He, Y; Hwang, DJ; McEwan, IJ; Miller, DD; Mohler, ML; Narayanan, R; Ponnusamy, S; Thiyagarajan, T | 1 |
| Dart, DA; Davies, L; Kandil, S; Lee, KY; Rizzo, SA; Westwell, AD | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Khandil, S; McGuigan, C; Pertusati, F; Westwell, AD | 1 |
| Barrett, RRG; Cotnoir-White, D; Diennet, M; Doyle, C; Gleason, JL; Mader, S; Nash, C; Thomson, AA | 1 |
| Wang, S; Xiang, W | 1 |
1 review(s) available for nitrogenase stabilizing-protective protein, bacteria and mdv 3100
| Article | Year |
|---|---|
Therapeutic Strategies to Target the Androgen Receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
9 other study(ies) available for nitrogenase stabilizing-protective protein, bacteria and mdv 3100
| Article | Year |
|---|---|
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
Topics: Active Transport, Cell Nucleus; Androgen Receptor Antagonists; Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Models, Chemical; Models, Molecular; Molecular Structure; Mutation; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Xenograft Model Antitumor Assays | 2014 |
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Benzamides; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Microsomes, Liver; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Permeability; Phenylthiohydantoin; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Tosyl Compounds | 2016 |
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Molecular Structure; Prostatic Neoplasms; Structure-Activity Relationship; Xylenes | 2016 |
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.
Topics: Animals; Cell Line, Tumor; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Nude; Models, Molecular; Nonsteroidal Anti-Androgens; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; RNA, Messenger; Triazoles | 2017 |
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents.
Topics: | 2017 |
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
Topics: Amides; Androgen Receptor Antagonists; Androgens; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Humans; Indoles; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Proteolysis; Rats; Receptors, Androgen; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Nitriles; Prostatic Neoplasms; Tosyl Compounds | 2019 |
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ether-A-Go-Go Potassium Channels; Humans; Hydrocarbons, Fluorinated; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Structure-Activity Relationship; Sulfhydryl Compounds; Tosyl Compounds | 2019 |
Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
Topics: Androgen Antagonists; Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorescence Resonance Energy Transfer; Fluorometry; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Molecular Structure; Nitriles; Phenylthiohydantoin; Pyridines; Structure-Activity Relationship; Tumor Cells, Cultured | 2022 |